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Emerging evidence suggests important differences
among protein kinase C (PKC) isozymes in terms of their
regulation and biological functions. PKC is regulated by
multiple interdependent mechanisms, including enzy-
matic activation, translocation of the enzyme in re-
sponse to activation, phosphorylation, and proteolysis.
As part of our ongoing studies to define the factors con-
tributing to the specificity of PKC isozymes, we pre-
pared chimeras between the catalytic and regulatory
domains of PKCa, -d, and -e. These chimeras, which pre-
serve the overall structure of the native PKC enzymes,
were stably expressed in NIH 3T3 fibroblasts. Their in-
tracellular distribution was similar to that of the endog-
enous enzymes, and they responded with translocation
upon treatment with phorbol 12-myristate 13-acetate
(PMA). We found that the potency of PMA for transloca-
tion of the PKCa/x chimeras from the soluble fraction
was influenced by the catalytic domain. The ED50 for
translocation of PKCa/a was 26 nM, in marked contrast
to the ED50 of 0.9 nM in the case of the PKCa/e chimera.
In addition to this increase in potency, the site of trans-
location was also changed; the PKCa/e chimera translo-
cated mainly into the cytoskeletal fraction. PKCx/e chi-
meras displayed twin isoforms with different mobilities
on Western blots. PMA treatment increased the propor-
tion of the higher mobility isoform. The two PKCx/e
isoforms differed in their localization; moreover, their
localization pattern depended on the regulatory do-
main. Our results emphasize the complex contributions
of the regulatory and catalytic domains to the overall
behavior of PKC.
Protein kinase C (PKC)1 is a major family of serine/threonine
kinases that plays a crucial role in cell signal transduction,
regulating cell growth and differentiation (1). Emerging evi-
dence suggests important differences among PKC isozymes
both in their regulation and in their biological roles. Thus, in
K-562 erythroleukemia cells, PKCa was implicated in mediat-
ing PMA-induced cytostasis, whereas PKCbII was involved in
proliferation (2). In RBL-2H3 basophilic leukemia cells, the
PKCa and -e isoforms preferentially inhibited phospholipase C
activity (3), whereas the PKCb and -e isoforms linked the mast
cell high affinity receptor for IgE to the expression of c-fos and
c-jun (4). In PKCb knockout mice, signaling through the anti-
gen receptor-dependent signaling pathway was markedly im-
paired (5). Not only may some PKC isoforms be active whereas
others not for a given response, but the actions of different
isoforms may even be antagonistic. In NIH 3T3 cells, for exam-
ple, PKCd arrested cell growth, whereas PKCe stimulated it (6,
7). As part of our ongoing studies to explore the basis of spec-
ificity of PKC isozymes, we have prepared chimeras between
the regulatory and the catalytic domains of PKCa, -d, and -e
and investigated their behavior in intact cells.
Protein kinase C consists of an N-terminal regulatory do-
main and a C-terminal catalytic domain. The catalytic domain
acts as a serine/threonine-specific protein kinase, and the reg-
ulatory domain is thought to inhibit this catalytic activity
through a so-called pseudosubstrate region near its N termi-
nus. Immediately C-terminal to this pseudosubstrate region is
a pair of highly conserved zinc finger structures termed the C1
domains that are the sites of phorbol ester binding on the
molecule and contribute to the association with anionic phos-
pholipid (8, 9). In the classic isozymes, a, bI, bII, and g, a
second domain in the regulatory region, the C2 domain, be-
stows Ca21 dependence. The novel isozymes, d, e, h, and u, lack
this region and correspondingly lack Ca dependence, although
they have a modified C2 homolog N-terminal to the C1 domain
(10). The individual C1 domains of PKC bind phorbol esters
with similar affinity to the intact PKC. X-ray crystallography of
the PKCd C1b domain revealed that the phorbol ester inserts
into a hydrophilic cleft in an otherwise hydrophobic surface,
promoting interaction of the C1 domain with the membrane
(11). It thus functions as a hydrophobic switch.
In the intact unstimulated cell, PKC is largely cytosolic with
some proportion depending on the isoform and the cell type
present in the membrane and cytoskeletal fractions (12, 13).
Phorbol ester addition leads to translocation of PKC from the
cytosol to the membranes, presumably reflecting enhanced
membrane affinity of the C1-phorbol ester complex. This trans-
location provides one measure of the response of specific PKC
isoforms in the context of the intact cell. Emerging understand-
ing suggests that translocation should not only depend on the
strength of the association between the C1 domain and the
membrane but should also be coupled to other factors contrib-
uting to the membrane association and the energetics of con-
formational changes in the enzyme upon activation. Receptors
for activated protein kinase C, the binding proteins for the
regulatory domain of PKC, have been described (14), which
stabilize the activated conformation of the enzyme (15). Spe-
cific substrates likewise can drive association, as elegantly
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shown by Jaken and co-workers (16). The state of phosphoryl-
ation of PKC is another important regulator that influences
both activity and localization (17, 18). Finally, the ability of the
pseudosubstrate domain to interact with the catalytic domain
is central to its function.
We report here that the catalytic domain of PKC influences
both the potency of phorbol ester for PKC translocation and the
compartment to which PKC is translocated in response to phor-
bol ester.
EXPERIMENTAL PROCEDURES
Construction of PKC Chimeras—Protein kinase C chimeras were
generated by swapping the regulatory and the catalytic domains of
PKCa, PKCd, and PKCe. The regulatory domain of PKCe was amplified
by polymerase chain reaction (PCR) employing high fidelity thermo-
stable vent DNA polymerase using the following primers: 59-CTC-
GAGATGGTAGTGTTCAATGGCCTTCTTA-39 and 59-GCTGCCTTT-
GACTAGTACCTTGAT-39. To amplify the catalytic domain of PKCe, the
primers we used were: 59-GTACTAGTCAAAGGCAGCTTTGGCAA-39
and 59-GACGCGTTCAGGGCATCAGGTCTTCACCAAA-39. The regula-
tory and catalytic domains of PKCd were amplified by utilizing the
primers below, respectively: 59-GGGCTCGAGATGGCACCCTTCCT-
TCGCATTT-39, 59-GCTGCCTTTGACTAGTACTTTT-39, 59-GTAC-
TAGTCAAAGGCAGCTTTGGCAA-39, and 59-CCACGCGTAATGTC-
CAGGAATTGCTCAAACTT-39. To amplify the regulatory and catalytic
domains of PKCa, we employed the following primers, respectively:
59-CGCTCGAGATGGCTGACGTCTTCC-39, 59-GCTGCCTTTGACTAG-
TACCATGAGGAA-39, 59-GTACTAGTCAAAGGCAGCTTTGGCAA-39,
and 59-CGACGCGTTACCGCGCTCTGCAGGATGG-39. To reduce the
chance of introducing mutations, we not only used high fidelity enzymes
but we also kept the number of PCR cycles low (8 cycles). To facilitate
subsequent cloning steps, into the inner PCR primers we introduced a
unique restriction site (SpeI). After 8 cycles of polymerase chain reac-
tion, we added an adenine overhang to the constructs with Taq polym-
erase at 72 °C after removing the primers, and we then ligated them
into the pGEM-T vector. From this point on we employed only classical
cloning techniques to further reduce the possibility of mutations in our
constructs. Using the pGEM-T vector as a shuttle vector we amplified
the different PKC domains separately by transforming them into bac-
teria; we then subcloned the catalytic domains into the vectors contain-
ing the regulatory domains using SpeI and MluI restriction enzymes.
An important advantage of this approach is that we could reconstruct
the wild type PKCa, -d, and -e isoforms using the same inserts as for the
chimeras, providing us with wild type controls constructed the same
way as the chimeras. Next we performed site-directed mutagenesis to
mutate the SpeI site back to the original sequence using the following
mutagenesis primers: for chimeras with PKCa regulatory domain, 59-
TCCTCATGGTGCTGGGCAAAGGCAGC-39; for chimeras with PKCd
regulatory domain, 59-CCAAAAAGTACTTGGCAAAGGCAGC-39; and
for those with PKCe regulatory domain, 59-CTTCATCAAGGTGTTAG-
GCAAAGGCAGC-39. We used the SpeI site for the selection. The chi-
meras along with the wild type PKC isozymes were then subcloned into
an epitope-tagging mammalian expression vector described in detail by
Olah et al. (19). The XhoI and MluI sites ensure unidirectionality, and
the vector attaches a C-terminal 12-amino acid tag to the end of the
proteins, originally derived from the C terminus sequence of PKCe.
Finally, our constructs were sequenced by Paragon Biotech Inc. (Balti-
more, MD) to assure that no mutations had been introduced. The
chimeras were designated as PKCx/y, where x and y refer to the regu-
latory and the catalytic domains, respectively. Thus, PKCa/d, for exam-
ple, refers to the chimera between the a regulatory domain and the d
catalytic domain.
Cell Culture and Transfection of Cells—NIH 3T3 cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with 4500 mg/liter
glucose, 4 mM L-glutamine, 50 units/ml penicillin, 50 mg/ml streptomy-
cin (Advanced Biotechnologies Inc., Columbia, MD) and 10% fetal calf
serum (Life Technologies, Inc.). The cells were transfected with either
the empty vector or the different PKC expression vectors using Lipo-
fectamine (Life Technologies, Inc.) following the procedure recom-
mended by the manufacturer. The transfected cells were subsequently
grown in selection medium containing 750 mg/ml G418 (Life Technolo-
gies, Inc.). After 12–18 days in selection medium, single colonies were
picked and subsequently screened for the presence of different PKC
chimeras by Western blot analysis. Where indicated, cells were treated
with different concentrations (0.01 nM–10 mM) of PMA (LC Laborato-
ries, Woburn, MA) for 1 h, 3 h, and 6 h at 37 °C; dimethyl sulfoxide was
added to the control cells. Analyses were routinely carried out on pools
of transfected cells, but all results were confirmed on individual clones.
Cell Lysis, Subcellular Fractionation, and Western Blot Analysis—
The cells were harvested into 20 mM Tris-Cl (pH 7.4) containing 5 mM
EGTA, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, and 20 mM leu-
peptin and lysed by sonication. The cytosolic fraction represents the
supernatant following centrifugation at 100,000 3 g for 1 h at 4 °C. The
Triton X-100 soluble particulate fraction was prepared by a 2-h extrac-
tion of the pellet with the same buffer containing 1% Triton X-100 and
a subsequent centrifugation for 1 h at 100,000 3 g. The remaining pellet
is the Triton X-100 insoluble fraction. The samples were subjected to
SDS-polyacrylamide gel electrophoresis according to Laemmli (20) and
transferred to nitrocellulose membranes. The protein content of indi-
vidual samples was determined (12) by staining the Western blots with
0.1% Ponceau S solution in 5% acetic acid (Sigma). The protein staining
was found to be linear up to 30 mg of protein/lane. The Ponceau S
staining was removed by several washes with phosphate-buffered sa-
line (pH 7.4); the membranes were blocked with 5% milk in phosphate-
buffered saline and subsequently immunostained with polyclonal anti-
bodies generated against a polypeptide corresponding to amino acids
726–737 of PKCe (Life Technologies, Inc.). In some cases the chimeras
containing the a and the d catalytic domains were detected with the
corresponding anti-catalytic domain antibodies from Upstate Biotech-
nology (Lake Placid, NY) and Research and Diagnostic Antibodies
(Berkeley, CA), respectively. Secondary antibodies were goat anti-rab-
bit IgG coupled to horseradish peroxidase (Bio-Rad), and the immuno-
reactive bands were visualized by the ECL Western blotting detection
kit purchased from Amersham Corp. The densitometric analysis of the
immunoblots and the normalization to the protein content of each
individual lane were performed as described (12).
Protein Kinase C Assay—Protein kinase C activity was assayed by
measuring the incorporation of 32P from [g-32P]ATP (Amersham Corp.)
into substrates (as described previously (21)) in the presence of 100
mg/ml phosphatidylserine and 1 mM PMA. Cell lysates were partially
purified on a HiTrap Q column (Pharmacia Biotech Inc., Uppsala,
Sweden) and 10 ml of the partially purified cell lysates were incubated
in assay buffer containing 20 mM HEPES, pH 7.5, 10 mM MgCl2, 0.5 mM
CaCl2, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 20 mM leupeptin,
10 mg/ml aprotinin (all purchased from Sigma), 50 mM ATP, 1 mCi of
[g-32P]ATP, and 50 mM/assay myelin basic protein (from bovine brain)
(Sigma) as substrate at 30 °C for 10 min. The reaction was stopped by
adding trichloroacetic acid at 10% final concentration. After centrifu-
gation for 5 min at 15 000 3 g a 25-ml aliquot of the supernatant was
spotted onto phosphocellulose disks (Life Technologies, Inc.). The disks
were washed three times in 0.5% phosphoric acid and three times in
distilled water. The bound radioactivity was measured by liquid scin-
tillation counting. The kinase assay was linear with time over this
incubation period, and at 50 mM substrate was linear with the amount
of protein over the range of cell lysates used in the assays.
[3H]PDBu Binding—[3H]PDBu binding was measured by using the
polyethylene glycol precipitation assay (21). Briefly, cell lysates (40–60
mg of protein/assay) were incubated with 20 nM [3H]PDBu in the pres-
ence of 100 mg/ml phosphatidylserine. Nonspecific binding, determined
in the presence of 30 mM nonradioactive PDBu, was subtracted to give
specific binding. Data presented represent triplicate determinations in
each experiment.
RESULTS
We have constructed protein kinase Ca, -d, and -e chimeras
to study the relative contributions of the regulatory and the
catalytic subunits of these isozymes to their behavior.
We have determined that these PKC chimeras can be stably
expressed in NIH 3T3 cells, bind [3H]PDBu, and exhibit cofactor-
dependent kinase activity as do the wild type PKC isozymes
(Table I, Fig. 1). Using a previously described tagging system
(19) we could readily distinguish the endogenous and overex-
pressed isozymes of PKCa/x and PKCd/x (sizes are determined
by the regulatory domain). In the case of PKCe/a and PKCe/d
we confirmed our findings by using anti-PKCa and anti-PKCd
anti-catalytic antibodies. Because the levels of these overex-
pressed enzymes as well as the levels of the overexpressed
PKCe/e were much higher than the endogenous PKCe, inter-
ference by the endogenous PKCe was not a problem. The anti-
bodies recognized the two previously described PKCe-specific
bands at 90 and 93 Kd (7) of the overexpressed PKCe. PKCd/e
Protein Kinase C Chimeras 22149
and PKCa/e chimeras also showed double bands on Western
blots, suggesting that the posttranslational phosphorylation of
the PKCe catalytic domain was similar to that of the wild type.
In contrast, the PKCe/a and PKCe/d chimeras show a single
band suggesting that the posttranslational modification of
PKCe occurs only on the catalytic domain.
To explore the role of the catalytic domains in phorbol ester
response, we determined the translocation and subcellular lo-
calization patterns of the different chimeras after PMA treat-
ment (Fig. 2). Based on the kinetics of translocation of the
endogenous PKCa, -d, and -e isoforms in these cells (12) (Table
II), we examined the effects on the chimeras of treatment with
varying doses of PMA for 1, 3, and 6 h. The translocation
dose-response curves were stable after 1 h of exposure to PMA,
and at this time point down-regulation was not yet detectable
(data not shown). Fig. 2 illustrates one representative dose-
response experiment using pooled transfected cells (at least
three experiments were performed at each time point). The
tagged overexpressed wild type PKC isozymes (PKCa/a,
PKCd/d, and PKCe/e) translocated with time courses and dose-
response curves similar to those of the endogenous enzymes
reported earlier (12), arguing against artifacts caused either by
the overexpression or by the e-epitope tag (Table II). Experi-
ments were also performed with at least one clone of each
chimera, yielding similar results to the pooled cultures.
The subcellular distribution of PKC chimeras in the un-
treated cells is summarized in Table III. The distribution of the
overexpressed wild type enzymes was similar to that reported
previously for the endogenous enzymes (12) except that 10% of
PKCd/d was found in the insoluble fraction. The control of
distribution in the case of PKCa/x (PKCa regulatory domain)
chimeras was dominated by the a regulatory domain. A role for
the catalytic domain was evident in the case of PKCe/a chi-
mera; moreover, the catalytic domain of PKCe seemed to have
some effect in bringing PKCa/e and PKCd/e into the insoluble
fraction (PKC e/e was also higher there as expected). The
PKCd/a distribution differed from that of both parent isozymes
with a much higher proportion in the Triton X-100 insoluble
fraction. The cofactor-dependent stimulation of kinase activity
was somewhat lower for PKCd/a than that of the other chime-
ras (see Fig. 1); on the other hand, the PKCd/a chimera showed
good [3H]PDBu binding activity (see Table I). How these dif-
ferences may be related to the higher portion in the Triton
X-100 insoluble fraction remains to be determined.
In the case of the PKCa regulatory chimeras, the catalytic
domain markedly influenced the apparent affinity of PMA for
the enzyme. PMA was less potent in translocating the wild type
PKCa/a than the PKCa/d and a/e chimeras. The dose-response
curves for the decrease in PKC in the soluble fraction were
quantitated and fitted to the Hill equation (Fig. 3) In the case
of wild type PKCa/a, the ED50 for translocation was 26 6 1 nM
(n 5 five experiments) (similar to that reported earlier for the
endogenous PKCa (12)) (Table II). It decreased to 9.1 6 0.3 nM
in the case of the PKCa/d chimera (n 5 five experiments) and
was yet an order of magnitude more sensitive in the case of the
PKCa/e chimera (ED50, 0.91 6 0.05 nM (n 5 five experiments)).
For the chimeras involving the d and e regulatory domains the
ED50 values for PMA-induced translocation were similar inde-
pendent of the specific regulatory or catalytic domain (PKCd/a,
9.3 6 0.1 nM; PKCd/d, 12.4 6 0.3 nM; PKCd/e, 8 6 1 nM; PKCe/a,
12 6 1 nM; PKCe/d, 7.4 6 0.2 nM; PKCe/e, 7.0 6 0.4 nM; n 5
three experiments for all values) (Fig. 4).
Not only did the PKCa/e chimera have a dose-response curve
that was shifted to the left, but the destination of translocation
changed; i.e. the chimera translocated mostly to the Triton
X-100 insoluble fraction. This shift in distribution was parallel
to a changing proportion of the PKCa/e chimera in the lower
band as compared with the upper band (easiest to observe in
the total PKC fraction). The lower band of PKCa/e was present
just in the Triton X-100 insoluble fraction, whereas the upper
band was predominantly in the cytosolic and particulate
fractions (Fig. 2).
The PKCd/e and PKCe/e chimeras also revealed a PMA de-
pendent shift in the proportions of the two bands with an
increase in the lower band at higher PMA concentrations. The
subcellular distribution of the two bands depended on the iden-
tity of the regulatory domain, whereas the presence of the two
bands depended on the e catalytic domain. Compared with
PKCe/e, PKCd/e and PKCa/e showed a reduced proportion of
the upper band present in the Triton X-100 insoluble fraction.
Unlike PKCe/e or PKCa/e, PKCd/e maintained large amounts of
the higher mobility isoform (lower band) in the cytosolic and
membrane fractions.
We determined the PMA dependence of the increase in the
lower band for the PKCx/e chimeras. The ED50 values were
similar to those observed for the decrease in the soluble frac-
tion (1.5 versus 0.91 nM for PKCa/e, 11.1 versus 8 nM for
PKCd/e, and 9.1 versus 7.0 nM for PKCe/e). We conclude that the
two processes occur in parallel.
DISCUSSION
A major objective is to dissect the factors regulating the flow
of information through the families of PKC isoforms present in
specific cell types. For therapeutic intervention, isoform selec-
tive ligands would greatly enhance specificity. Unfortunately it
is becoming clear that current in vitro binding assays to recom-
binant PKC isozymes neglect major contributions to selectivity
in the intact cells. Thus, phorbol esters have a 4-fold weaker
affinity for PKCe compared with PKCa in vitro (21), whereas
PMA is 160-fold more potent for translocation of PKCe than of
PKCa in mouse keratinocytes (13). Selectivity depends, more-
over, on the specific cell type. In NIH 3T3 cells, the selectivity
of PMA for PKCe compared with PKCa is only 3.5-fold versus
the 160-fold in the keratinocytes (12, 13). Our current results
demonstrate that the factors controlling the phorbol ester in-
teractions depend on the catalytic domain of PKC as well as on
the phorbol ester binding C1 domains. Identification of the
specific mechanisms by which the catalytic domain contributes
to the translocation remains to be determined.
One possible mechanism by which the catalytic domain could
influence protein kinase C unfolding, and indirectly phorbol
ester binding, would be through the strength of the interaction
TABLE I
[3H]PDBu binding of PKC chimeras
Specific [3H]PDBu binding of the different PKC chimeras was deter-
mined by the polyethylene glycol precipitation assay described under
“Experimental Procedures.” Data presented show the mean values 6
S.E. with triplicate determinations of a single experiment. Two other
independent experiments gave similar results. The values for the con-
trol and the PKCa/a chimera are expressed as pmol of [3H]PDBu
bound/mg of protein, and the values for the other chimeras were further
normalized based on their level of expression relative to the PKCa/a
chimera.
[3H]PDBu bound
pmol/mg protein
Control 1.12 6 0.01
PKCa/a 6.34 6 0.07
PKCa/d 4.1 6 0.1
PKCa/e 7.75 6 0.03
PKCd/a 4.18 6 0.07
PKCd/d 4.27 6 0.09
PKCd/e 5.53 6 0.05
PKCe/a 4.55 6 0.08
PKCe/d 4.17 6 0.06
PKCe/e 4.32 6 0.05
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between the pseudosubstrate region and the catalytic site.
Cantley and co-workers (22) have examined in depth the sub-
strate selectivities of the PKC isozymes. The a pseudosubstrate
peptide shows similar Km values for the a and d catalytic
activities (e was not reported) (22). Also, we had observed
similar relative activities of the PKCa and PKCe pseudosub-
strates for PKCe (21). Although the regulation of PKC isozymes
by second messengers and membrane components has been
extensively studied (1, 23), the mechanisms by which PKCs can
separately modulate signals from distinct receptor pathways
remain under active investigation. In cells stimulated with
hormones or phorbol esters, most of the cellular PKC translo-
cates to new subcellular sites, including the plasma membrane
(24), cytoskeleton (15), nucleus (15, 25), and elsewhere (15).
Furthermore, within the same cell various isozymes may each
be localized to different subcellular sites after cell stimulation
FIG. 1. Kinase activity of protein ki-
nase C chimeras. PKC chimeras were
partially purified from cell lysates, and
protein kinase activity was assessed by
measuring the incorporation of 32P from
[g-32P]ATP into substrates in the pres-
ence and absence of 100 mg/ml phosphati-
dylserine (PS) and 1 mM PMA as described
under “Experimental Procedures.” Data
represent the mean 6 S.E. of three inde-
pendent experiments. The values for the
control and the PKCa/a chimera are ex-
pressed as pmol/min/mg of protein, and
the values for the other chimeras were
further normalized based on their level of
expression relative to the PKCa/a chi-
mera. For the experiments shown in the
figure we used myelin basic protein as
substrate.
FIG. 2. Translocation and localiza-
tion patterns of PKC chimeras in-
duced by PMA treatment. NIH 3T3 fi-
broblasts overexpressing various PKC
chimeras were treated with increasing
concentrations of PMA. Samples for SDS-
polyacrylamide gel electrophoresis were
prepared and Western immunoblotting
was performed as described under “Ex-
perimental Procedures.” The figure illus-
trates one representative experiment.
The fractions were labeled in the figure as
follows: total, total fraction; sol, soluble
fraction; part, Triton X-100 soluble frac-
tion; and ins, Triton X-100-insoluble frac-
tion. Similar results were obtained in
three to five sets of independent experi-
ments at each time point.
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(25, 26). Translocation of protein kinases to new sites neces-
sarily alters their access to substrates (15).
Increasing evidence implicates both the regulatory and the
catalytic domains in modulating PKC translocation. It has
been previously proposed that membrane binding of PKC in
vivo reflects the binding of the activated enzyme to the an-
chored receptors for activated protein kinase C (27). This oc-
curs via the regulatory domain of PKC (14), stabilizing the
active conformation of the enzyme (15). Protein kinase Ce was
also reported to bind to actin through a binding site located
within the regulatory domain (28). Conversely, there is strong
evidence for the role of the catalytic domain in isozyme-specific
localization. Although PKCbI and -bII differ only at the C
terminus, they localize differently (29), strongly arguing that
unique C-terminal sequences may target these isoforms to dif-
ferent subcellular locations (30). Also, using PKCa and -bII
chimeras, a region within the catalytic domain of bII PKC was
shown to be responsible for its isotype-specific translocation to
the nucleus (31). Targeting may also occur by binding to cellu-
lar proteins that function as substrates. Examples include myr-
istoylated alanine-rich C kinase substrate, g-adducin, and ki-
nesin light chain (29, 32). Furthermore, the constitutive
membrane association of the truncated PKC regulatory do-
main, in contrast to the cytosolic localization of the holoen-
zyme, argues for a role of the catalytic domain (33). Finally,
immunohistochemical studies reveal a role for the catalytic
domain in the pattern of localization and translocation of PKCd
and PKCe chimeras.2 Complementing these other studies, the
findings described here show that the catalytic domain can
control the potency of PMA for driving translocation.
Not surprisingly, phosphorylation has emerged as an impor-
tant mechanism of PKC regulation (17). Phosphorylation pro-
vides negative charges on the so-called activation loop of PKC
that is necessary for enzymatic activity (34, 35). This
transphosphorylation is followed by two autophosphorylation
steps. Both occur on the C terminus of the enzyme, further
stabilizing the catalytically active conformation and also mak-
ing the enzyme soluble (18). Our studies support a role for
phosphorylation in determining the localization of PKCe, with
PMA changing the proportion of the higher mobility isoform of
PKCx/e chimeras in the Triton X-100 insoluble fraction. At the
same time the localization patterns of these chimeras depend
2 Q. J. Wang, P. Acs, J. Goodnight, P. M. Blumberg, H. Mischak, J. F.
Mushinski, submitted for publication.
TABLE II
Comparison of the affinity of PMA to induce translocation of the
endogenous PKC isozymes and the overexpressed PKC isozymes with
e-epitope tag
NIH 3T3 fibroblasts transfected with PKC chimeras were treated by
0.01 nM–1 mM PMA, the soluble fraction was prepared, and Western
immunoblotting was performed as described under “Experimental Pro-
cedures.” The amount of the enzyme was quantitated by densitometry,
and dose-response curves and ED50 values were calculated from the Hill
equation. Points represent the mean 6 S.E. of at least three independ-
ent experiments. The ED50 values for the endogenous PKCs are from
Ref. 12.
ED50 for the endogenous
PKCs (12)
ED50 for the e-epitope
tagged PKCs
nM nM
PKCa 21 6 1.2 26 6 1
PKCd 11 6 0.3 12.4 6 0.3
PKCe 6 6 0.8 7.0 6 0.4
TABLE III
Subcellular localization of various PKC chimeras in untreated cells
The distribution of the individual PKC isozymes among the fractions
obtained by centrifugation was determined based on the protein levels
measured in these fractions. (The soluble fraction contains about 45–
50%, the Triton X-100 soluble particulate fraction contains about 5%,
and the Triton X-100 insoluble fraction contains about 45–50% of the
total protein.) Similar results were obtained in a second set of inde-
pendent experiments.
Soluble fraction Particulatefraction
Triton X-100
insoluble fraction
% of total
PKCa/a 80 10 10
PKCa/d 80 10 10
PKCa/e 80 5 15
PKCd/a 30 15–20 50
PKCd/d 65–75 15–25 10
PKCd/e 50–55 15–20 30
PKCe/a 80 10 10
PKCe/d 50–55 10–15 30–35
PKCe/e 50–55 10–15 30–35
FIG. 3. PMA-induced changes in the level of PKCa/x chimeras
in the cytosolic fraction of NIH 3T3 fibroblasts. NIH 3T3 fibro-
blasts transfected with PKCa/a, -a/d, and -a/e chimeras were treated by
the indicated doses of PMA. The soluble fraction was prepared, and
Western immunoblotting was performed as described under “Experi-
mental Procedures.” The amount of the enzyme was quantitated by
densitometry and expressed as the percentage of the amount of isozyme
present in the soluble fraction in the untreated cells. The illustrated
dose-response curves were calculated from the Hill equation. Points
represent the average of five independent experiments 6 S.E.
FIG. 4. ED50 values of PMA-induced translocation of PKC chi-
meras in NIH 3T3 cells. NIH 3T3 fibroblasts transfected with PKC
chimeras were treated with 0.01 nM–1 mM PMA; the soluble fraction was
prepared, and Western immunoblotting was performed as described
under “Experimental Procedures.” The amount of the enzyme was
quantitated by densitometry and expressed as the percentage of the
amount of isozyme present in the soluble fraction in the untreated cells.
Dose-response curves were calculated from the Hill equation, and the
calculated ED50 values are shown in this diagram. Points represent the
average of at least three independent experiments.
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on the regulatory domain. The fact that the phosphorylation
state of PKCs as well as PKC chimeras can change after PMA
treatment emphasizes that protein phosphatases may play a
cell-specific role in targeting different PKCs during
translocation.
PMA translocates chimeras that have the same regulatory
domains but different catalytic domains with potencies that
differ by an order of magnitude. Phorbol esters bind to the C1
domains of PKC providing a hydrophobic cap over a hydrophilic
cleft (11). At the same time their side chains contribute to
stabilizing the enzyme at the membrane. Our results suggest
that binding of PMA reveals other site(s) that facilitate(s)
translocation (shift in ED50) and that play(s) a role in targeting
PKC to separate subcellular sites (translocation of PKCx/e chi-
meras to the insoluble fraction).
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